Emerging studies suggest Retatru tide , a dual stimulator targeting both GLP-1 and GIP , could offer a notable advancement for obesity treatment. Early human trials have shown considerable losses in abdominal tissue, conceivably exceeding current body composition medications . Despite this, more stu